Foresters Investment Management Company Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 12.2% during the fourth quarter, Holdings Channel reports. The fund owned 1,639,656 shares of the biopharmaceutical company’s stock after selling 228,350 shares during the quarter. Pfizer makes up 1.4% of Foresters Investment Management Company Inc.’s portfolio, making the stock its 5th biggest position. Foresters Investment Management Company Inc.’s holdings in Pfizer were worth $71,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Advocacy Wealth Management Services LLC grew its stake in shares of Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 258 shares during the last quarter. Winch Advisory Services LLC grew its stake in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 336 shares during the last quarter. 1 North Wealth Services LLC bought a new stake in shares of Pfizer during the fourth quarter worth $40,000. Ruggie Capital Group bought a new stake in shares of Pfizer during the fourth quarter worth $44,000. Finally, Contravisory Investment Management Inc. lifted its holdings in shares of Pfizer by 182.6% during the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 745 shares during the period. 71.88% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently commented on PFE shares. Goldman Sachs Group started coverage on shares of Pfizer in a report on Tuesday, May 28th. They set a “conviction-buy” rating on the stock. Credit Suisse Group reiterated a “buy” rating and set a $48.00 price target on shares of Pfizer in a report on Monday, May 6th. Citigroup reiterated a “neutral” rating and set a $41.00 price target on shares of Pfizer in a report on Wednesday, February 20th. JPMorgan Chase & Co. set a $46.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, April 30th. Finally, Barclays reiterated a “hold” rating and set a $41.00 price target on shares of Pfizer in a report on Thursday, May 9th. Thirteen analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $46.00.

Shares of NYSE:PFE opened at $43.08 on Thursday. The firm has a market cap of $239.77 billion, a PE ratio of 14.36, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 52 week low of $35.73 and a 52 week high of $46.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.10. The business had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. Pfizer’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 7th. Investors of record on Friday, May 10th were issued a $0.36 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.44 annualized dividend and a yield of 3.34%. Pfizer’s payout ratio is 48.00%.

In related news, insider Rady A. Johnson sold 8,700 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $41.13, for a total value of $357,831.00. Following the transaction, the insider now owns 59,797 shares in the company, valued at $2,459,450.61. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $42.83, for a total transaction of $642,450.00. Following the completion of the transaction, the insider now owns 124,994 shares in the company, valued at approximately $5,353,493.02. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2019/06/13/pfizer-inc-nysepfe-shares-sold-by-foresters-investment-management-company-inc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: How Investors Can Profit from Options Trading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.